Encorafenib (BRAFTOVI)

Melanoma, advanced or metastatic, with BRAF V600E or BRAF V600K mutation

Colorectal cancer, advanced or metastatic, with BRAF V600E mutation

Melanoma, advanced or metastatic, with BRAF V600E or BRAF V600K mutation

• Dose – Oral: 450 mg once daily continuously until disease progression or unacceptable toxicity
• Given in combination with binimetinib

Colorectal cancer, advanced or metastatic, with BRAF V600E mutation

• Dose – Oral: - 300 mg once daily continuously until disease progression or unacceptable toxicity
• Given in combination with cetuximab or panitumumab

Available as 75 mg hard gelatin capsules. Capsules should NOT be opened. Store at room temperature and protect from moisture.

BRAF Inhibitor

Take with or without food

If a dose is missed, patients should be instructed to take it as soon as they can if it is within 12 hours of the missed dose. If it is over 12 hours since the missed dose, patients should skip the missed dose and resume with the next scheduled dose.

Common: Retinal pigment epithelial detachment, Visual impairment, Diarrhea, Nausea, Vomiting, Fatigue , ALT/AST increase, GGT increase, Glucose increase, Arthralgia, Myopathy, Headache, Acneiform dermatitis, Alopecia, Hyperkeratosis, Hand-foot skin reaction.

Less Common: Tachycardia, Uveitis, QT prolongation, Secondary cutaneous or non-cutaneous malignancies, Hemorrhage, Hypertension, Venous thromboembolism.

The adverse effects listed above are not exhaustive. Please refer to the relevant product monograph for full details.

Baseline before treatment: CBC & differential, platelets, creatinine, sodium, potassium, calcium, magnesium, alkaline phosphatase, ALT, albumin, ECG, LDH, MUGA scan or echocardiogram, blood pressure, GGT.

During treatment: Creatinine, sodium, potassium, calcium, magnesium, alkaline phosphatase, ALT, albumin, LDH, blood pressure, MUGA scan or echocardiogram, ECG, dermatologic evaluation, GGT.

If clinically indicated: HbA1c, ophthalmologic consult.

• May increase the risk for QT interval prolongation. Avoid concurrent therapy with drugs associated with QTc prolongation and/or Torsades de pointes, if possible. If unavoidable, monitor for QT prolongation or cardiac arrhythmias.
• Avoid grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.
• This drug can impact or be impacted by metabolic enzymes for absorption and excretion. Many drugs can also affect or be affected by these enzymes, so please consult with pharmacy to assess for interactions.
• Current drug interaction databases should be consulted for more information.

• Avoid in pregnancy and lactation.
• Secondary malignancies have been reported with encorafenib including cutaneous squamous cell carcinoma, new primary melanomas, and non-cutaneous malignancies. Skin examination should be performed prior to, during, and after treatment has ended.
• Ocular toxicity has been reported. Patients with any new or worsening visual disturbance should be referred  to an ophthalmologist.

BC Cancer. BC Cancer Drug Manual. Encorafenib. Vancouver, British Columbia: BC Cancer Agency. Available at: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Encorafenib_monograph.pdf. Updated December 1, 2022. Accessed January 22, 2024.

Lexicomp. Encorafenib Monograph. In: Lexi-Drugs. Hudson, Ohio: Lexi-Comp, Inc. Available at: https://online-lexi-com.qe2a-proxy.mun.ca/lco/action/doc/retrieve/docid/patch_f/6667978?cesid=5WoD99420Yf&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dencorafenib%26t%3Dname%26acs%3Dfalse%26acq%3Dencorafenib. Updated January 24, 2024. Accessed January 28, 2024.

Cancer Care Ontario. Encorafenib Monograph. Drug Formulary. Toronto, Ontario: Cancer Care Ontario. Available at: https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/74026. Updated July 2023. Accessed January 22, 2024.

Pfizer Canada-ULC. BRAFTOVI® Product monograph. Kirkland, Quebec. Update March 30, 2021.